Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD

Brief Summary

The goal of this exploratory, mixed-method design study is to gather qualitative and quantitative data obtained through interviews and questionnaires with veterans who are currently enrolled at the VA for healthcare. The main question this study aims to answer is: How do veterans diagnosed with PTSD and enrolled for care at the VA understand MDMA-assisted therapy for PTSD? Using a story-completion approach, participants will be provided with a brief story starter involving a fictitious character and scenario and asking them to complete the story. Few contextual details will be offered about the character. In responding to ambiguous cues, participants are thought to project their conscious and subconscious perceptions about the phenomenon in question onto the story, a useful method for exploring stigmatized topics. The purpose of this exercise is to ascertain the participants attitudes and perceptions regarding MDMA-Assisted Therapy.

Intervention / Treatment

Condition or Disease

  • Post Traumatic Stress Disorder

Phase

Study Design

Study type: OBSERVATIONAL
Status: Completed
Study results: No Results Available
Enrollment: 30 (ACTUAL)
Time Perspective: Cross-Sectional
Observational Model: Cohort

Masking

Clinical Trial Dates

Start date: Aug 08, 2022 ACTUAL
Primary Completion: Mar 23, 2023 ACTUAL
Completion Date: Mar 23, 2023 ACTUAL
Study First Posted: Jun 08, 2023 ACTUAL
Last Updated: Jun 20, 2023

Sponsors / Collaborators

Lead Sponsor: N/A
Lead sponsor is responsible party
Responsible Party: N/A

Veterans will be informed of the study by their VA providers (Behavioral Health Clinic, PCMHI, PTSD Clinic, CDRP, Primary Care). Veterans who are interested will have their contact information passed on to the study investigators. Once screened and enrolled in the study veterans will complete a brief demographics form, and three brief symptom screening questionnaires: PTSD Checklist for DSM-5, 5-Item screener for PTSD, and Patient Health Questionnaire 9. Participants then engage in the recorded interview during which they are provided with a brief story starter, as described above. In the story, a fictitious veteran with a diagnosis of PTSD is offered an opportunity to enroll in a clinical trial and receive MDMA-Assisted therapy. Participants are asked to share what questions, concerns, hopes, and expectations may be present for the fictitious veteran in the story. Interviews will then be transcribed and the PI and the collaborators will read all transcriptions and generate recurring themes that can be reliably coded. The investigators will then code the transcripts for the presence of themes. Data analytic plans include calculating the prevalence of each theme and examining their correlates with measures of severity of symptoms as well as any demographic variables. It is hoped that this data can inform educational and other roll-out efforts within the VA system as MDMA-Assisted therapy approaches FDA approval as a treatment for PTSD.

Eligibility Criteria

Sex: All
Minimum Age: 18
Age Groups: Adult / Older Adult
Healthy Volunteers: Yes

Inclusion Criteria:

* Veterans enrolled in VA care
* Active diagnosis of PTSD, as determined by the referring provider or confirmed by medical records.
* Age 18 or older
* Fluent in written and spoken English

Exclusion Criteria:

* Cognitively impaired to the extent that patient cannot comprehend the survey
* Has already completed the interview

Primary Outcomes
  • Screening tool for depressive symptoms. Scores range from 0-27 with lower scores indicating better outcomes

  • Screening tool for PTSD symptoms. Scores range from 0-80 with lower scores indicating better outcomes

  • Screening tool for PTSD symptoms. Scores range from 0-4 with lower scores indicating better outcomes.

More Details

NCT Number: NCT05895318
Other IDs: 061006
Study URL: https://clinicaltrials.gov/study/NCT05895318
Last updated: Sep 29, 2023